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Background and purpose: Move for Change is an online pan-European patient
survey based on the European Parkinson’s Disease Association (EPDA) Char-
ter for People with Parkinson’s Disease (PD), which states that all PD patients
have the right to: be referred to a doctor with a specialist interest in PD;
receive an accurate diagnosis; have access to support services; receive continu-
ous care; and take part in managing their illness.
Methods: This part of the survey focuses on the ﬁnal two elements of the
Charter. It was administered online through the EPDA website and through
aﬃliated patient associations’ websites. A total of 1591 questionnaires were
received and 1546 were analysed (97.2%).
Results: Approximately half of the patients (53.0%) consulted a neurologist
regularly (every 4–6 months). Consultations were usually arranged as part of a
follow-up process (65.5%) and lasted for 15–30 min (63.2%), with 16.1% last-
ing <10 min and 17.9% lasting >30 min. Patients were largely satisﬁed with
the attention they received (63.2%) but just 11.6% of patients were involved
in treatment decisions, and 39.1% prepared a list of symptom changes for dis-
cussion. Two hundred caregivers also took part in the survey, and 71.4% felt
included in the treatment plan by the doctor.
Conclusions: These results highlight that PD disease-management is driven by
the clinician; he/she arranges consultations and makes the majority of manage-
ment decisions, rather than patients being included in the process. This survey
can be used to raise awareness for PD patients, encouraging greater involve-
ment in the management of PD.
Introduction
It is estimated that ~1.2 million people in Europe have
Parkinson’s disease (PD) [1]. The neurodegenerative
nature of the disease can lead to a greatly diminished
quality of life [2–4]. PD has a high socioeconomic
burden, estimated to be €13.9 billion across Europe
and expected to worsen due to the increased risk of
PD in our aging population [5–8].
The Charter for People with Parkinson’s Disease
was launched by the European Parkinson’s Disease
Association (EPDA), with the World Health Organi-
zation, in 1997 as part of its campaign against PD [9].
To understand the disease management approach for
PD across Europe, and to evaluate the inﬂuence that
the Charter has had since it was introduced, the Move
for Change campaign was launched in 2010; a series
of three pan-European surveys were devised to
identify the highs and lows of PD treatment and to
evaluate the quality of disease management from the
patients’ perspective [10].
Part I of the survey focused on the ﬁrst two state-
ments of the Charter: all PD patients have the right
to be referred to a doctor with a specialist interest in
PD and to receive an accurate diagnosis. Over 2000
completed questionnaires from 35 European countries
were summarized [11], and the results indicated that
only 11.9% of respondents had received their initial
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diagnosis from a doctor specializing in PD, 43.8% of
the respondents had not received a consultation from
a doctor specializing in PD in the 2 years following
diagnosis, and almost half of the respondents were
dissatisﬁed with the manner in which their diagnosis
had been delivered. Part II of the survey focused on
access to support services, based on a comparable
data set of 1752 questionnaires from 32 European
countries [12]. These data identiﬁed that PD patients
most commonly have access to general practitioners
(GPs; 87.0%) and neurologists (90.0%), but less
so to a doctor specializing in PD (68.0%). GPs were
highlighted to be ‘very helpful’ by only 35.6% of
patients, which was concerning considering they were
one of the most accessible healthcare professionals
(HCPs).
The European Parkinson’s Disease Standards of Care
Consensus Statement, Volume I [11], has been devel-
oped by the EPDA and a multidisciplinary team of
HCPs, Parkinson’s specialists, patients and their
caregivers to demonstrate the standards of care that
PD patients should receive throughout Europe. This
document is used in conjunction with the Move for
Change survey results to lobby for the standardization
of Parkinson’s care across Europe and was presented
to Members of the European Parliament in November
2011.
This paper presents the ﬁndings of the ﬁnal part
of the Move for Change campaign, which was avail-
able for online completion in 2012, and which
focuses on the ﬁnal two parts of the Charter, i.e. ‘all
patients have the right to receive continuous care’
and ‘to take part in the management of their illness’.
This survey asked participants to indicate how often
they had consultations with various HCPs and how
involved they had been in decisions regarding their
disease management. Evidence suggests that patients
who are actively involved in decisions regarding their
disease management are more satisﬁed with the
decided methods than those who are less involved in
the decision [14]. Additionally, by involving patients
in the decision-making process, better outcomes can
be achieved at a reduced cost [15]. Interestingly, it is
the involvement in the process rather than making
the ﬁnal decision which demonstrates the most bene-
ﬁt for patients [16]. Patients with PD are no excep-
tion, and a recent survey revealed a strong desire
amongst patients to be involved in shared decision
making [17].
Now that the Move for Change campaign is com-
plete, the data from all three surveys will be used by
the EPDA to demonstrate the unmet need in PD
across Europe and to lobby for change, highlighting
the areas of disease management that must be altered
in order to ensure that the rights of the Charter are
met across Europe. In addition, the complete survey
data set will allow for intra-country analyses and help
PD organizations and HCPs in diﬀerent countries to
lobby for change based on the beneﬁts shown in other
countries.
Methods
The Move for Change Part III survey was launched
online on 12 April 2012 in conjunction with the
European Parkinson’s Action Day and ran until 31
December 2012. Measures taken to aid promotion of
this survey included: translated website banners;
advertisements in quarterly Member Organizations’
(MOs’) national journals and external journals;
emails from MOs to their members; and promotion
by the EPDA.
The survey complied with the Code of Conduct for
pharmaceutical market research of the European
Pharmaceutical Market Research Association and no
adverse events were reported. Approval from the Clin-
ical Research Ethics Committee or Independent
Review Board was not required because drug therapy
was not addressed. The methods used for Part III of
this survey have been published previously [11].
The survey
The survey consisted of 19 questions covering: patient
demographics; regularity of PD patient consultations
with various HCPs; duration that PD patients have to
wait to arrange a consultation; the involvement of PD
patients in treatment and management decisions; and
the level of PD patient preparation before a consulta-
tion. Translated into 24 languages by the local PD
organizations, the survey was completed in local
language. The complete questionnaire is included as an
online supplement to this manuscript of volume II [12].
Results
Assimilation of questionnaire information
A total of 1591 forms were received from patients in
30 diﬀerent countries, and 1546 (97.2%) were analy-
sed. This is comparable to Part I of the survey (2149
received, 96.2% analysed [11]) and to Part II (1786
received, 98.1% analysed [12]). The remaining 45
questionnaires were rejected largely due to unan-
swered questions. Although results from countries
with less than eight respondents (i.e. ≤0.5% of the
total survey sample) were included in regional- and
European-level analyses, data from these countries
© 2014 The Author(s). European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
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were not analysed at an individual country level. A
full analysis report can be accessed on the EPDA
website at http://www.epda.eu.com/en/projects/move-
for-change/part-3/ [18] which demonstrates a consider-
able variation across Europe. It is important to note
that data reported at a European level are not
representative of the current situation in individual
countries.
Demographics
Of the 1546 questionnaires analysed: 50.7% were from
men; the most common age group was 60–69 years
(35.9%); and the age of respondents ranged from
<30 years (0.4%) to ≥80 years (4.5%). Only 1.1% of
patients were diagnosed before 1986, whilst 77.6%
were diagnosed from 2006 to 2012; the median disease
duration was 3 years (2006–2012). Table 1 shows the
regional distribution and demographic data for
respondents.
HCP consultation details
Figure 1 demonstrates the regularity with which
patients consult various clinical and allied health ser-
vices, 53.0% of patients indicating they attended con-
sultations with a neurologist and 40.9% consulting
their GP on a 4- to 6-monthly basis. Unfortunately it is
not known whether these patients went on to have a
follow-up appointment with a neurologist as this ques-
tion was not raised within the survey. Additional data
have been provided in Fig. S1 in Volume I [11] to show
the frequency of consultations compared with duration
of disease; patients with shorter disease duration con-
sulted HCPs on a more regular basis than those with
longer duration. For patients with the most advanced
PD (diagnosis before 1980) the neurologist and GP are
still the most frequently consulted HCPs, with at least
4-monthly consultations indicated by 37.5%.
Other clinical HCPs visited every 4–6 months were
a neurologist specializing in PD (25.1%), a hospital
doctor (19.5%) and a PD specialist nurse (14.2%).
For the allied services, the physiotherapist was con-
sulted on a weekly or monthly basis by 40.1% of
patients; this was three-fold more than the percentage
of patients consulting a neurologist at the same regu-
larity. The time taken to arrange a consultation with
a GP (69.5%) or physiotherapist (38.7%) was less
than 2 weeks.
Figure 2 shows that most consultations were
arranged as part of a routine follow-up process
(65.5%), with only 12.9% indicating that a consulta-
tion was arranged because medication was ineﬀective
or because of a change in symptoms (11.9%). The
trend in clinical consultation duration across Europe
is 15–30 min (63.2%); 79.3% of these patients indi-
cated they had received adequate attention, whilst
17.2% felt rushed. An additional 17.9% of patients
stated that clinical consultations with a doctor (GP,
hospital doctor or neurologist) lasted more than
30 min, and 92.8% of these felt that the time was
adequate for their requirements.
When asked how they prepared for their HCP con-
sultations, 62.4% prepared a list of questions to take
to the consultations and only 39.1% wrote a list of
symptom changes to discuss with the HCP. Just
10.7% took notes when discussing points during the
consultation.
Table 1 Geographical region distribution of respondents
Global region
Mean gendera
Mean age
(years)
Mean years
since diagnosis
(years)
Forms
analysed (N)
Percentage of
total forms
analysed (%)Men (%) Women (%)
Eastern Europe
Bosnia and Herzegovinab, Czech Republic, Hungary,
Polandb, Russiab, Romaniab, Ukraine
42.9 56.1 58.7 8.8 98 6.3
Northern Europe
Denmark, Finland, Ireland, Norway, Sweden, UK
45.9 53.7 61.4 6.5 492 31.8
Southern Europe
Croatiab, Cyprusb, Greece, Israel, Italy, Malta,
Portugalb, Slovenia, Spain, Turkeyb
56.5 43.3 64.4 8.2 561 36.3
Western Europe
Austria, Belgium, France, Germany, Luxembourg,
The Netherlands, Switzerland
50.3 49.7 61.5 6.5 384 24.8
Not stated 54.5 45.5 65.5 8.0 11 0.7
Totala 50.7 49.0 62.4 7.3 1546 100.0
a0.3% of respondents did not state gender; bincluded in regional analysis; national sample too small to analyse individually.
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Disease management decisions
Figure 3 shows that only 11.6% of patients made
treatment-related decisions on their own, with most
(50.6%) making the decision with the HCP. However,
34.2% were uninvolved with decisions relating to their
treatment. Decisions relating to further disease
management, however, showed 37.5% made a collab-
orative decision with the HCP, compared with 28.4%
who were uninvolved in the decisions and 14.4% who
made the decision alone. It should be noted that
19.7% did not answer this question.
Information sources and availability
Information on the treatment and management
options was available from a variety of sources: PD
organizations (64.1%); Internet searches (62.4%);
friends (62.4%); and the GP (60.5%; Fig. 4). Table 2
shows the type of information available to patients
during consultations, and how helpful this was. Most
patients indicated that information on medication
frequency (49.6%), medication type (43.5%) and
symptoms (35.3%) was the most clearly explained and
helpful. Information on fatigue (44.5%), appropriate
diet (44.4%) and pain management (40.0%) was not
available.
Caregivers of PD patients
A section for the caregivers and partners of the
PD patients was included to provide their views on
HCP consultations and the dedication towards both
the patient and the caregiver themselves. Only 200
responded to this section of the survey; 8.5% of
these did not attend consultations with the patient,
59.0% helped the patient to prepare a list of ques-
tions, 46.5% helped with a list of symptom
changes.
The majority of caregivers felt that a consultation
of ≥30 min was enough time to talk about their own
concerns (60.7%) and 71.4% felt that the doctor had
tried to understand the symptoms and involve the
caregiver in the treatment plan.
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Discussion
The Move for Change survey was designed to identify
the areas of PD care in Europe which are not meeting
the standards indicated in clinical guidelines and the
EPDA Charter [9,19–22], and is the largest European
patient survey focused on this topic. Here, the ﬁnal
part of the survey is presented, which concentrated on
the management of PD and continued treatment for
patients. A large majority of consultations across
Europe are arranged as part of a routine follow-up
process, suggesting that treatment is driven by the
HCP and not by patient needs. Most patients feel
they receive adequate attention from the HCP during
the consultations, which commonly last between 15
and 30 min. Satisfaction levels increased with longer
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durations of the consultation. It is important to note
that these data may not be an accurate representation
of clinical consultation satisfaction; more dissatisﬁed
patients are likely to be those with a poor relationship
with their clinician or Parkinson’s support networks
and may not have been aware of the survey in order
to respond. Frequent and prolonged physiotherapy
treatment was common, suggesting chronic treatment.
Evidence to support the eﬀectiveness of this type of
lengthy treatment with high referral rates is limited
[23] and guidelines state that treatment should ideally
consist of short-lived interventions [24].
The survey population is comparable to those seen
in Parts I and II [11,12] as well as the general
European PD population; other studies have shown
comparable demographics [25,26].
The HCPs who were consulted most frequently and
who had the shortest access time were the GPs and the
0 10 20 30 40 50 60 70 80
Other
Newspapers
Healthcare professional
Information brochures
GP
Internet search
Friends
PD organizations
Percentage (%)
64.1
62.4
62.4
60.5
27.9
23.9
20.8
6.6
Figure 4 Percentage of total respondents
indicating the sources of information
used by patients to help them make deci-
sions regarding management (n = 1546).
Table 2 Percentage of total respondents indicating the level and type of information available to them during consultations with an HCP
It does
not
apply
Not
comfortable
raising this
No
information
available
Printed
information
available
Brieﬂy
mentioned
Explanation
clear and
helpful
Did not
understand
Symptoms 1.9 1.2 15.5 11.1 23.0 35.3 1.2
Medication 2.1 0.6 8.9 8.0 25.0 43.5 1.5
Medication frequency 1.7 0.1 3.2 13.4 19.8 49.6 1.1
Side eﬀects 2.9 1.3 24.4 8.2 25.4 21.0 1.7
Treating advanced Parkinson’s 20.2 1.5 29.9 3.8 12.5 16.4 0.6
If medication has not been
taken
8.3 0.8 32.4 4.6 19.5 19.0 0.5
Other medications 6.5 0.6 39.5 4.7 17.3 13.2 1.0
Foods 6.7 0.5 44.4 3.8 16.0 11.6 0.4
Health issues 4.7 1.3 39.3 3.3 21.2 12.2 0.6
Fatigue 5.4 1.1 44.5 2.8 15.5 11.1 1.0
Sleeping better 8.4 0.6 40.9 2.8 16.2 12.9 0.3
Coping with pain 13.8 0.6 40.0 2.5 12.8 9.4 0.5
Bowel and bladder issues 10.5 1.6 36.9 3.1 16.9 10.9 0.3
Exercise 1.4 0.2 13.8 6.4 25.2 33.9 0.5
Changes in mood 10.5 0.8 39.9 2.5 14.4 10.0 0.3
Assistance at home 17.7 0.6 39.2 2.5 9.6 7.7 0.5
Financial help 14.7 1.4 48.8 2.3 5.3 5.0 0.2
Support organizations 6.9 1.2 35.9 8.1 15.7 9.8 0.5
Help with daily living 4.3 0.3 25.0 5.6 23.2 19.8 0.5
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neurologists. Yet, only half of the patients had regular
scheduled appointments with their neurologist (53.0%),
suggesting that there could be under-treatment in the
remaining patients. Indeed, neurologist care is
associated with a reduction in hospitalization for
psychosis and traumatic injury, and an increased fre-
quency of neurologist consultations is associated with
improved outcomes; Willis et al. [27] indicated that ﬁve
or more outpatient visits with a neurologist over a
period of 4 years was associated with a decrease in hos-
pitalizations. These investigators suggest that the lower
risks of hospitalization associated with neurologist care
could indicate an improved ability of these HCPs to
recognize and treat PD symptoms and complications.
This underscores the need for a broader implementa-
tion and easier access to neurologist care for Parkinson
patients across Europe, and in particular to neurolo-
gists with expertise in movement disorders.
The results relating to PD specialist nurses concur
with the data from Part II of the survey, highlighting
that they do not have access but as a service they are
very helpful [11]. PD nurse specialists are widely felt
to be a critical part of the multidisciplinary team
approach of PD patients, but there is little evidence to
support this impression [28,29]. There are some recent
data to suggest that PD patients cared for by a spe-
cialist nurse are more satisﬁed with their treatment
and care than those consulting a general neurologist
[30]. PD specialist nurses can improve the well-being
of patients without impacting on healthcare costs
through medication and symptom management
support [30,31]. Moreover, clinical practice guidelines
recommend regular consultations with a PD nurse
specialist [22,32]. These presented data highlight poor
accessibility to PD nurse specialists, reducing the reali-
zation of these potential beneﬁts.
The Move for Change Part II data highlighted the
neurologist and GP to be the most accessible HCPs,
but suggested an increased understanding of PD and
its symptoms would be necessary to treat a patient
appropriately, in particular for GPs [12]. The EPDA
Charter stipulates that a PD patient should be
referred to a doctor specializing in PD in order to
receive an accurate diagnosis but does not specify
which professional should be primarily responsible for
continued care. Our feelings are that the complex and
progressive nature of PD justiﬁes periodic consulta-
tions with an expert in PD, interleaved with consulta-
tions with generically active professionals. These Part
III data suggest a high frequency of consultations
with GPs and neurologists, although this appeared to
be driven by the clinicians and not by the actual needs
of the patients. It is crucial that collaboration between
patients and HCPs takes place to ensure that consul-
tations are arranged at an appropriate time in order
to achieve the best possible clinical outcomes. It is rec-
ommended that patients or their caregivers should be
leading the timing of the consultations, so that they
are held at a stage when the patient has poignant
points to discuss. Observations in patients with
inﬂammatory bowel disease suggest that such a
patient-driven arrangement of consultations could
result in a reduction in consultation frequency and
also a reduction of costly ‘no shows’ [33]. Objective
measures of disease progression or markers of vital
complications such as falls will help in delivering a
more individually tailored follow-up system, without
the risk of losing patients who fail to report to their
physician despite clear indications to do so. The use
of automated follow-up (e.g. ambulatory sensing)
could assist with this [34].
The economic burden of disease with regard to
patient-driven medicine must also be considered; care
and services available will vary in diﬀerent countries
according to their healthcare system. Previous studies
have shown that adherence to medication is improved
if there is better collaboration between patients and
clinicians [35], and compliance with medication in PD
has been shown to reduce healthcare costs [36].
Involving patients in medical decisions, e.g. using
shared decision approaches, can also help to reduce
costs [37,38]. Additionally, better care, professional-
ized networks and an active role for patients can be
implemented without changing the reimbursement
system [39]. Future work will examine whether patient
healthcare status aﬀects the intensity of medical
consumption, e.g. patients who utilize private health
insurance systems may have more dedicated options.
The act of being involved in disease-management
decisions is thought to lead to patient satisfaction; the
level of information the patients consider they have
received regarding treatment discussion is a predictor
of their satisfaction, rather than the actual involve-
ment [14]. Evidence suggests 40–80% of medical infor-
mation provided by the HCP is forgotten immediately
[40], and only 10.7% of patients in this survey indi-
cated that they took notes during a consultation. This
could suggest a link between patients being truly
involved in the decision-making process and those
who are less engaged during the consultation. Most
patients felt that the level of information in several
areas of PD was limited, particularly in areas of
fatigue, pain management, and advanced PD care.
This could lead to a lower number of patients being
able to make an informed decision regarding their
disease management. There is also evidence to suggest
that the transition into palliative/advanced care is
poorly understood [41,42]. HCPs should provide
© 2014 The Author(s). European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
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patients with certiﬁed sources of information to avoid
any bias and potential dangers of uncertiﬁed informa-
tion; online portals can be useful resources for
patients and, if the community is large enough, a self-
correcting and improving element is likely to exist. In
the Netherlands, for example, patients can use a web
application to create an online encyclopaedia of
relevant and useful information about coping with
everyday challenges of PD [39].
Most patients in the Move for Change survey made
collaborative decisions regarding disease and treat-
ment with their GP, which would suggest that they
were content with the outcomes. However, it can
rightly be questioned whether these decisions were
truly made as part of a shared decision process, where
patients have full access to all medical information
and can weigh the importance of each element of the
decision process [43,44]. Furthermore, the low per-
centage of consultations arranged due to dissatisfac-
tion with medication (12.9%) could be correlated with
the percentage of those who are not involved in treat-
ment (34.2%) and disease management (28.4%) deci-
sions. This is clinician-driven treatment rather than
patient-driven care, and indicates that consultations
are not being held when they should be in order to
optimally treat the patient. Patients with a lower
educational background are more likely to change
treatment [45], so an improvement could lead to bet-
ter-informed patients with regard to their disease and
treatments available. Subsequently, they will be less
likely to change their treatment, and a decision will be
focused on necessity and beneﬁt rather than concern
and misunderstanding. It has been demonstrated that
good patientclinician collaboration can improve
medication adherence in chronic conditions [35],
which is important to achieve treatment outcomes and
quality-of-life for the patient [46]. It is possible that a
lack of patient involvement in the decision process
partially explains the disappointing treatment compli-
ance in patients with PD [47,48].
A diagnosis of PD also has a great impact on the
caregivers (partner, family and friends of the patient)
[49,50]. Both the motor and non-motor aspects of PD
can result in a high burden and strain, particularly
with more advanced disease [51]. Dedicated support
for the caregiver is essential, to improve their quality-
of-life and also help minimize rising healthcare costs
[52,53]. Informal caregivers have the potential to sig-
niﬁcantly reduce the cost and care burdens of PD that
would ordinarily fall on the health services [54], with
evidence in the UK suggesting that this could be up
to £119 billion annually [55]. This survey included a
section for informal caregivers to indicate their
involvement with preparation for consultations and
during the appointment. Only 13% of the analysed
forms included responses from the caregiver, hence
the results must be interpreted very cautiously. How-
ever, this small group responded very consistently
with a high percentage (91.5%) stating that they
attended the consultation. The survey only superﬁ-
cially touched upon the many issues that are relevant
for caregivers and more work is required here e.g.
using the Parkinson’s Disease Questionnaire  Carer
(PDQ-Carer), allowing informal caregivers to high-
light their speciﬁc areas of concern [56]. The EPDA is
very supportive of informal caregivers and is in the
process of developing a second Consensus Statement
for Carers [57]; this will be a sister publication to the
Consensus Statement for People with Parkinson’s Dis-
ease [13] and will focus on raising awareness of the
informal caregivers’ needs.
This study has several limitations, most of which
have been previously highlighted in Parts I and II of
the survey [11,12]. The most important to note is the
possibility of response bias due to the methods by
which it was promoted and completed. As the survey
was only available online, participation was limited to
those with Internet access who are likely to be well
informed about their disease, may consult with their
clinician more frequently and have a more favourable
view on the quality of their consultations than
patients who are less well informed. It is important to
note that there may be under- or over-representation
of participating countries, and the level of response
is not necessarily indicative of the national PD
population.
To conclude, the Move for Change survey has dem-
onstrated that the EPDA Charter has been adapted
only partially throughout Europe, and various unmet
needs have been identiﬁed. Although PD patients are
seen regularly by a physician, there is a lack of con-
sultations with a PD specialist [11]. There is also a
need for greater adoption of multidisciplinary care
across Europe to provide the beneﬁts PD patients
need [12]. This ﬁnal part of the survey has identiﬁed
that, although on a regular basis, consultations were
largely routine and not arranged by the patient based
on their needs. The use of a multidisciplinary team
and additional support services in the treatment and
care of PD has been shown to be beneﬁcial and
encouraged across Europe, but access to some services
such as PD specialist nursing is limited. Additionally,
although most patients felt they had been involved in
decisions regarding their disease management, true
shared decision making is presumably still rare, and
there are several vexing problems of PD (e.g. consti-
pation) for which information was not adequately
provided. It has been demonstrated that ‘participatory
© 2014 The Author(s). European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
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medicine’, where patients act as partners in their care
with their HCPs, results in improved care and can
also contain costs [58]. Therefore, it is important that
the dialogue between patients and HCPs is improved
so that patients become empowered enough to discuss
changes in their condition and understand their treat-
ment regimen, whilst the HCPs maintain the power to
ensure the treatment plan is appropriate for the
patient.
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